Compare Matson Inc (MATX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Sanofi SA — how do they compare? Matson Inc trades at $214.45 (market cap $6.41B), while Sanofi SA trades at $43.58 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 16.3× Matson Inc's market cap, and Sanofi SA pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| MATX | SNY | |
|---|---|---|
Market Cap | $6.41B | $104.30B |
Sector | Technology | Health |
52-Week High | $223.55 | $52.34 |
52-Week Low | $88.05 | $41.33 |
Enterprise Value | $7.01B | $124.19B |
Dividend Yield | 0.71% | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $214.45, up 2.76% with strong earnings momentum after beating Q2 2026 EPS estimates of $3.79 with $4.27 actual. The stock shows bullish technical signals with support at $200 and resistance at $209. Fundamentally, the company maintains solid profitability with 13.41% net margin and 17.21% ROE, supported by raised full-year guidance after strong Q2 results.
MATX presents a compelling investment case with 27.3% upside to consensus price target of $265, supported by 66.7% analyst buy ratings. Key risks include exposure to Trans-Pacific trade volatility and competitive shipping markets, but resilient consumer demand and premium China service position the company for continued growth.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
